These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 22564130)
41. [Prevention of NSAID gastropathy: the difference between a coxibs and the addition of a PPI]. Lems WF; Kuipers EJ Ned Tijdschr Geneeskd; 2010; 154(45):A2663. PubMed ID: 21118596 [TBL] [Abstract][Full Text] [Related]
42. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. Tannenbaum H; Bombardier C; Davis P; Russell AS; J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802 [TBL] [Abstract][Full Text] [Related]
43. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Lanas A; Ferrandez A Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792 [TBL] [Abstract][Full Text] [Related]
44. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. Szeto CC; Sugano K; Wang JG; Fujimoto K; Whittle S; Modi GK; Chen CH; Park JB; Tam LS; Vareesangthip K; Tsoi KKF; Chan FKL Gut; 2020 Apr; 69(4):617-629. PubMed ID: 31937550 [TBL] [Abstract][Full Text] [Related]
45. Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs? Yeomans ND BMC Med; 2015 Mar; 13():56. PubMed ID: 25858463 [TBL] [Abstract][Full Text] [Related]
46. Questionnaire on NSAID gastropathy among Dutch rheumatologists. Steen KS; Lems WF; Dijkmans BA Clin Rheumatol; 2000; 19(3):193-4. PubMed ID: 10870652 [TBL] [Abstract][Full Text] [Related]
47. Gastrointestinal risk of non-steroidal anti-inflammatory drugs and gastroprotective agents used in the treatment of osteoarthritis in elderly patients: A nationwide retrospective cohort study . Han MH; Nam JH; Noh E; Lee EK Int J Clin Pharmacol Ther; 2019 Nov; 57(11):531-541. PubMed ID: 31397273 [TBL] [Abstract][Full Text] [Related]
48. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Moodley I Cardiovasc J Afr; 2008; 19(2):102-7. PubMed ID: 18516356 [TBL] [Abstract][Full Text] [Related]
49. [Effects of nonsteroidal anti-inflammatory agents on the gastrointestinal tract]. Bures J; Rejchrt S; Kopácová M; Siroký M Cas Lek Cesk; 2002 Oct; 141(21):673-9. PubMed ID: 12564374 [TBL] [Abstract][Full Text] [Related]
51. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Price-Forbes AN; Callaghan R; Allen ME; Rowe IF Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035 [TBL] [Abstract][Full Text] [Related]
52. Current state of therapy for pain and inflammation. Abramson SB; Weaver AL Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S1-6. PubMed ID: 16168076 [TBL] [Abstract][Full Text] [Related]
53. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Peura DA; Goldkind L Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S7-13. PubMed ID: 16168079 [TBL] [Abstract][Full Text] [Related]
54. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785 [TBL] [Abstract][Full Text] [Related]
55. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Hollander D Am J Med; 1994 Mar; 96(3):274-81. PubMed ID: 8154516 [TBL] [Abstract][Full Text] [Related]
56. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Gabriel SE; Jaakkimainen L; Bombardier C Ann Intern Med; 1991 Nov; 115(10):787-96. PubMed ID: 1834002 [TBL] [Abstract][Full Text] [Related]
57. SHORT- AND LONG-TERM EFFECTS OF NSAIDS ON THE GASTROINTESTINAL MUCOSA: COMPLEX ANALYSIS OF BENEFITS AND COMPLICATIONS PREVENTION. Hnepa YY; Chopey IV; Chubirko KI; Bratasyuk AM Wiad Lek; 2021; 74(4):1011-1018. PubMed ID: 34156022 [TBL] [Abstract][Full Text] [Related]
58. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Peura DA Am J Med; 2004 Sep; 117 Suppl 5A():63S-71S. PubMed ID: 15478855 [TBL] [Abstract][Full Text] [Related]
59. [Adherence with proton pump inhibitor therapy, by continuously taking nonsteroidal anti-inflammatory drugs]. Pimanov SI; Makarenko EV; Dikareva EA Ter Arkh; 2015; 87(4):58-61. PubMed ID: 26087636 [TBL] [Abstract][Full Text] [Related]